Skip to content

Discontinued — last reported Q1 '25

Interest Income at other companies

BioMarin Pharmaceuticals logo
BioMarin PharmaceuticalsBMRN
$22.56M+18.7%
Capricor Therapeutics logo
Capricor TherapeuticsCAPR
$2.9M+298%
uniQure logo
uniQureQURE
$5.23M+26.7%
Wave Life Sciences logo
Wave Life SciencesWVE
$5.29M+84.0%
Edgewise Therapeutics, Inc. logo
Edgewise Therapeutics, Inc.EWTX
$5.1M-1.1%
Dyne Therapeutics, Inc. logo
Dyne Therapeutics, Inc.DYN
$8.76M+23.3%

Segments

By segment

See full
All Other Segments-$6.36M+37.6%

Other financials

Income statement

See full
Revenue$730.8M-1.9%
Operating income-$300.4M-961%
Net income$331.0M+174%
EPS (diluted)-$4.60-1,343%

Balance sheet

See full
Cash & equivalents$464.5M+92.8%
Total debt$198.5M-3.4%
Total equity$1.5B+31.7%
Total assets$3.2B-8.3%

Cash flow

See full
Operating cash flow-$202.7M+65.3%
CapEx$2.1M-95.2%
Free cash flow-$204.8M+67.3%

Valuation

See full
Market cap$1.76B-63.1%

Profitability

See full
Operating margin-50.8%-1.6pp
Net margin4.6%+2.4pp
FCF margin-28.7%-9.2pp

Returns & leverage

See full
Return on equity-23.6%-28.5pp
Debt / equity0.1×0.0×
Current ratio4.6×+0.6×

Where this comes from

Reported directly by Sarepta Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:InvestmentIncomeInterest.

The official record: Sarepta Therapeutics, Inc.’s 10-Q, filed May 6, 2025, on SEC EDGAR. View the filing →

Ask your AI about Sarepta Therapeutics, Inc.'s interest income.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Sarepta Therapeutics, Inc.'s interest income?
Sarepta Therapeutics, Inc. (SRPT) reported interest income of $10.19M in Q1 2025.
What does interest income mean?
Income earned from interest-bearing assets including cash deposits, money market funds, treasury securities, corporate bonds, and customer financing receivables.